Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.39 |
| ▸ | TYMP | P19971 | 4/20 | 0.43 |
| ▸ | TK1 | P04183 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | ALB | P02768 | 2/20 | 0.39 |
| ▸ | BLM | P54132 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL9392093 | 1.00 | TYMP (0.43) | TYMPTK1LMNAALBBLM | |
| SCHEMBL28129115 | 0.95 | TK1 (0.43) | TYMPTK1LMNAALBBLM | |
| SCHEMBL3477 | 0.95 | TK1 (0.43) | TYMPTK1LMNAALBBLM | |
| Hydrochloric Acid SCHEMBL28100272 | 0.94 | TK1 (0.42) | TYMPTK1LMNAALBBLM | |
| SCHEMBL28839372 | 0.91 | TK1 (0.40) | TYMPTK1LMNAALBBLM | |
| SCHEMBL3092317 | 0.85 | TK1 (0.52) | TK1POLB | |
| Stavudine SCHEMBL1674560 | 0.82 | ALDH1A1 (0.67) | TYMPTK1LMNAALBBLM | |
| SCHEMBL9443814 | 0.82 | TK1 (0.35) | TYMPTK1LMNAALBBLM | |
| SCHEMBL9392106 | 0.80 | POLA1 (0.51) | TK1POLB | |
| Idoxuridine SCHEMBL846579 | 0.78 | TK1 (0.67) | TK1LMNABLMADRA1ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1849470-B2 | ANTICANCER DRUG CONTAINING ALPHA, ALPHA, ALPHA-TRIFLUOROTHYMIDINE AND THYMIDINE PHOSPHORYLASE INHIBITOR | TAIHO PHARMACEUTICAL CO LTD (JP) | 2024-03-20 | — | — | EP | disclosed |
| CN-109771437-B | Application of trifluorothymidine in preparing medicine for treating triple negative breast cancer | 西安交通大学医学院第一附属医院 | 2023-03-17 | — | — | CN | disclosed |
| CN-108203437-B | Preparation method and application of two kinds of tipiracil impurities | 海南先声药业有限公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-110642910-B | Thymidine derivative and preparation method and application thereof | 南开大学 | 2020-10-30 | — | — | CN | disclosed |
| CN-110642910-A | Thymidine derivative and preparation method and application thereof | 南开大学 | 2020-01-03 | — | — | CN | disclosed |
| CN-108203437-A | Preparation method and application of two kinds of tipiracil impurities | 江苏先声药业有限公司 | 2018-06-26 | — | — | CN | disclosed |
| EP-1849470-B1 | ANTICANCER DRUG CONTAINING ALPHA, ALPHA, ALPHA-TRIFLUOROTHYMIDINE AND THYMIDINE PHOSPHORYLASE INHIBITOR | TAIHO PHARMACEUTICAL CO LTD (JP) | 2017-06-21 | — | — | EP | disclosed |
| US-RE46284-E1 | Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2017-01-24 | — | — | US | disclosed |
| US-7799783-B2 | specifically 5-chloro-6-(1-(2-iminopyrrolidinyl)methyl)uracil hydrochloride; breast cancer or digestive cancer; combination called TAS-102; modified dosing schedule | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2010-09-21 | — | — | US | disclosed |
| EP-1849470-A1 | ANTICANCER DRUG CONTAINING ALPHA, ALPHA, ALPHATRIFLUOROTHYMIDINE AND THYMIDINE PHOSPHORYLASE INHIBITOR | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-10-31 | — | — | EP | disclosed |
| US-20060167031-A1 | Method of administrating an anticancer drug containing alpha, alpha, alpha-trifluorothymidine and thymidine phosphorylase inhibitor | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167031-A1 | Method of administrating an anticancer drug containing alpha, alpha, alpha-trifluorothymidine and thymidine phosphorylase inhibitor | TYMP, MTAP, PNP | ADRA1A 2819/4885TYMP 1/4885TK1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.